Federal prosecutors identify Protectus LLC and five related Nevada companies as the commercial network allegedly used to recruit medical providers, distribute skin-substitute products, assist government billing, divide reimbursements, and pay commissions within Michael McMillan’s charged healthcare fraud scheme.
WASHINGTON, DC, August 23, 2026 — Protectus LLC occupies a central position in the federal indictment of Michael McMillan, with prosecutors portraying the Nevada company and related entities as the operational middle layer connecting skin-substitute products, participating medical providers, government reimbursements, sales representatives, and disputed financial transfers.
The charging document alleges that McMillan used Protectus companies to recruit physicians, podiatrists, and other providers; supply wound-care products without upfront payment; assist with claims; monitor government reimbursements; calculate percentage-based invoices; and compensate representatives who expanded the alleged network.
That description makes Protectus more than a conventional distributor within the government’s theory, because the companies allegedly coordinated the commercial steps through which a product reached a patient, a claim reached a federal program, and reimbursement was divided among participants.
McMillan has not been convicted; the allegations remain unproven, and prosecutors must establish every required element beyond a reasonable doubt, while the indictment identifies Protectus LLC and related entities but does not name them separately as defendants in its caption.
Protectus Was a Group of Six Nevada Companies
The indictment defines Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC collectively as “Protectus,” alleging that McMillan owned and controlled every company within that Nevada-based group.
This collective definition matters because specific communications, invoices, payments, and accounts sometimes involve different entities, even though prosecutors present their activities as part of one connected operation aimed at recruiting providers and generating federally reimbursed skin-substitute business.
According to the Northern District of Texas case announcement, McMillan allegedly owned Protectus LLC and related entities, offered providers products through an illegal kickback arrangement, and received approximately $174 million through the disputed commercial structure.
Calling Protectus LLC the alleged vehicle for the scheme captures its leading role, but the indictment’s broader language requires equal attention to affiliated companies that allegedly handled consulting, technology, wound-care, product, invoicing, and payment functions over several years.
The Alleged Middleman Connected Products with Payouts
Prosecutors describe Protectus as an intermediary positioned between skin-substitute supply and clinical reimbursement, enabling the organization to influence provider recruitment, product availability, billing support, invoice timing, payment allocation, representative compensation, and the financial information communicated throughout the network.
Skin substitutes, sometimes called cellular or tissue-based products, allografts, or wound grafts, can assist wound closure or skin growth when appropriately selected, while federal programs generally reimburse covered products according to the quantity used and the applicable price per square centimeter.
The indictment does not claim that Protectus merely sold boxes at a fixed wholesale price and left providers to handle everything independently; instead, prosecutors allege ongoing involvement from product placement through claim payment, invoice issuance, and commission distribution.
That continuing role could become crucial at trial, since the government may argue that Protectus possessed unusually broad visibility into what providers billed, what government programs paid, what practices retained, and what sales representatives earned from each successful reimbursement.
Provider Recruitment Started the Alleged Pipeline
The government alleges that McMillan, acting through Protectus and with unnamed co-conspirators, recruited physicians, podiatrists, nurse practitioners, and other medical providers to use the companies’ skin-substitute products in exchange for financial returns linked directly to government reimbursement.
Sales representatives allegedly explained the profit-sharing arrangement to prospective providers, meaning recruitment was not limited to introducing a product’s clinical features, availability, or handling requirements, but reportedly included specific descriptions of the money a participating practice could retain.
During a March 2024 meeting cited by prosecutors, McMillan allegedly described an average thirty-five-percent provider rebate and explained that a practice collecting $180,000 monthly from Medicare could retain approximately $63,000 under the Protectus arrangement.
That presentation could support the prosecution’s inducement theory if jurors conclude the projected earnings were offered to influence federally reimbursed purchases, while defense counsel may characterize the discussion as lawful pricing information presented within an uncertain and complicated reimbursement marketplace.
No Upfront Cost Allegedly Shifted Provider Risk
Protectus allegedly supplied skin-substitute products without requiring providers to pay before using them, allowing participating practices to apply the materials, submit claims, and wait for a government coverage decision before receiving a corresponding invoice from the company.
When a government program denied reimbursement, prosecutors say Protectus generally did not charge the provider for that product, insulating the practice from acquisition loss while leaving the intermediary responsible for collecting only when the underlying public payment succeeded.
When reimbursement arrived, however, Protectus allegedly invoiced the practice for about sixty to seventy percent of the amount paid, allowing the provider to retain about thirty to forty percent and often realize thousands of dollars from an approved claim.
Prosecutors characterize the retained portion as an illegal kickback rather than a legitimate discount, although the defense can dispute whether the arrangements satisfied recognized commercial protections, reflected genuine risk allocation, or possessed the criminal purpose alleged by the government.
Government Payment Allegedly Determined Every Share
The reimbursement-contingent design sits at the heart of the indictment because the provider allegedly paid nothing after a denial, Protectus collected only after successful reimbursement, and the representative’s commission depended upon money Protectus received from the participating practice.
This sequence allegedly aligned the financial interests of clinicians, the intermediary, and recruiters around the same government decision, creating a structure in which larger or more frequent reimbursements could increase returns throughout multiple levels of the commercial network.
Ordinary medical distribution may involve credit terms, delayed payment, volume discounts, returns, and collection risk, but prosecutors contend Protectus crossed a legal boundary by guaranteeing providers a percentage of federal payments and allegedly concealing that economic reality from program administrators.
The eventual courtroom dispute will therefore turn on substance rather than vocabulary, because describing a transfer as a rebate, discount, commission, consulting payment, or profit does not, by itself, establish whether the arrangement was lawful or criminal.
QuickBooks Invoices Allegedly Recorded the Formula
One October 2022 invoice described in the indictment reported that a provider collected $53,625.60, retained $16,087.68, and owed Protectus Technologies LLC $37,537.92, producing the exact thirty-to-seventy allocation alleged elsewhere in the charging document.
Prosecutors may use that invoice to show a reimbursement split calculated after payment rather than a conventional product price established independently, while the defense can challenge whether one accounting entry accurately represents the parties’ entire contractual and economic relationship.
Another July 2023 episode allegedly involved Protectus LLC sending a Texas provider an invoice exceeding $82,000, after which a practice employee complained that the calculation reflected thirty-five-percent profit although a newer agreement promised forty percent.
McMillan allegedly instructed a Protectus employee to correct that calculation, a brief communication that prosecutors may portray as direct managerial confirmation of the promised provider margin, subject to defense challenges concerning context, meaning, completeness, and criminal intent.
Sales Representatives Expanded the Alleged Network
The indictment alleges that representatives recruited practices, described the profit-sharing offer, and received compensation calculated from amounts Protectus collected after government programs reimbursed providers, extending the same payment-dependent structure from the clinic relationship into the sales organization.
Protectus allegedly paid about $27 million to representatives connected with participating providers, while commission reports reportedly tracked whether insurers had paid underlying claims before the company released compensation tied to those reimbursed transactions.
A November 2022 email exchange cited by prosecutors concerned a commission report totaling $44,035.92 and an alleged omission exceeding $6,400, with a Protectus employee explaining that commissions could be paid only on insurance payments reported by the provider’s office.
An August 2023 message similarly explained that one provider invoice would appear on the representative’s next commission statement because the practice paid it during August, illustrating how Protectus allegedly monitored claim proceeds, invoice receipts, and recruiting compensation across successive accounting periods.
Protectus Allegedly Managed More Than Product Delivery
Prosecutors say McMillan and Protectus employees either billed government programs on behalf of medical providers or assisted those providers with submissions, placing the intermediary close to claim information that determined whether products qualified for Medicare, TRICARE, or CHAMPVA reimbursement.
That billing role matters because a distributor ordinarily may not know every detail a clinician reports, yet the indictment alleges Protectus personnel could identify missing information, recommend resubmission, issue invoices after payment, and reconcile amounts associated with specific claims.
In a May 2024 episode, a provider reportedly told Protectus that Medicare paid $9,024 for one product claim and denied another; an employee then identified missing Box 19 information and advised the practice to resubmit the denied claim.
Protectus then allegedly issued a $5,865.60 invoice for the paid claim, representing 65% of the reported reimbursement and leaving 35% with the provider, thereby connecting billing guidance, payment confirmation, and percentage-based invoicing in one documented sequence.
Box 19 Became an Alleged Concealment Point
The indictment says providers were required to disclose their actual acquisition price, including applicable discounts, rebates, refunds, and other adjustments, through information entered within Box 19 of the professional claim submitted for Medicare reimbursement.
Prosecutors allege that McMillan and Protectus submitted claims, helped submit claims, or advised providers to report inflated prices that did not reflect what practices effectively paid after reimbursement-linked reductions, thereby concealing the arrangement’s actual economics from government administrators.
During the March 2024 meeting, McMillan allegedly said he reviewed every Medicare claim to ensure Protectus products were billed at prices exceeding what medical providers actually paid, a statement likely to receive close examination if admitted at trial.
Defense lawyers can challenge the government’s interpretation by testing claim instructions, pricing definitions, adjustment timing, employee practices, provider responsibility, reliance upon billing guidance, and whether any disputed information was knowingly false, material, or personally attributable to McMillan.
Five Providers Illustrate a Multistate Operation
The indictment describes five anonymized medical providers, including a physician in Arlington, Texas; a nurse practitioner in Dallas; a podiatrist in McKinney, Texas; and podiatrists in Santa Monica, California, and Payson, Utah.
Those examples connect Protectus to providers across several states while establishing significant alleged activity within the Northern District of Texas, where payment transfers, communications, participating practices, and representative accounts help explain the federal venue despite McMillan’s Nevada residence.
The anonymous labels do not establish guilt for every referenced clinician, employee, or representative, and responsible reporting should avoid identifying uncharged participants through speculation while the government, defense, witnesses, and court determine what evidence can lawfully enter the record.
The Financial Scale Centers Protectus in the Case
Prosecutors allege that government healthcare programs paid about $268 million for claims connected with the arrangement, that providers retained about $94 million, and that McMillan and Protectus received about $174 million through the disputed reimbursement structure.
Those figures position Protectus as the principal commercial clearing point in the government’s narrative, because the intermediary allegedly collected most of the reimbursed money before using part of its receipts to compensate representatives and support broader corporate or personal spending.
An NBC 5 Dallas-Fort Worth report on the unsealed cases described allegations that providers retained thirty to forty percent, representatives received approximately $27 million, and McMillan used proceeds for luxury homes, vehicles, and a private aircraft.
All announced totals remain allegations rather than adjudicated loss findings, and later proceedings could distinguish among legitimate product value, eligible treatment, disputed remuneration, claim materiality, recovered property, and money prosecutors can reliably attribute to charged conduct.
Protectus Accounts Appear in Transactional Counts
Counts Three through Nine accuse McMillan of conducting seven transactions exceeding $10,000 with property allegedly derived from the charged conspiracies, and several identified purchases originated from bank accounts held in the name of Protectus LLC.
The indictment connects one Protectus LLC account with a $60,000 transaction involving a 2023 Lamborghini Urus and a roughly $260,000 transaction involving Las Vegas property, while another Protectus account allegedly funded later California real-estate and Cadillac transactions.
Other identified transactions allegedly originated from McMillan’s personal accounts or an account associated with Elite Elevated Enterprises LLC, including a September 2025 transfer of approximately $2.56 million connected with a 1997 Cessna Citation VII private aircraft.
These allegations give Protectus a financial-tracing role beyond product distribution, although prosecutors must still establish that the relevant money constituted criminally derived property and that McMillan possessed the knowledge required for each separate transactional count.
Nine Counts Create Distinct Legal Questions
Count One charges conspiracy to commit healthcare fraud, Count Two charges conspiracy to defraud the United States and pay healthcare kickbacks, and Counts Three through Nine concern monetary transactions allegedly involving proceeds derived from specified unlawful activity.
The government reported seizing assets valued at approximately $35 million, but seizure does not establish guilt or guarantee permanent forfeiture, because ownership, tracing, lawful revenue, substitute-property rules, third-party interests, valuations, and proportionality can remain contested.
Protectus LLC’s appearance throughout the factual allegations and transaction table does not itself make the company criminally liable, just as McMillan’s ownership does not relieve prosecutors from proving his knowing participation and required intent for every count.
A National Takedown Increased the Case’s Visibility
McMillan’s prosecution formed part of the 2026 National Health Care Fraud Takedown, which federal officials said charged 455 defendants, including ninety doctors and other licensed professionals, in alleged schemes involving more than $6.5 billion across numerous jurisdictions.
Within the Northern District of Texas, authorities announced seven cases against thirteen defendants involving more than $365 million in alleged fraudulent billing, making McMillan’s approximately $268 million wound-care matter the district’s largest announced prosecution by claimed payment scale.
The national initiative also emphasized data analytics, payment suspensions, provider revocations, civil recoveries, and asset seizures, demonstrating that modern healthcare enforcement follows not only medical records but also corporate relationships, reimbursement concentrations, invoices, commissions, banking activity, and unusual spending.
The Middleman Model Presents Compliance Risks
Manufacturers, distributors, consultants, and sales organizations should examine arrangements in which a single intermediary supplies products, finances inventory, assists with claims, tracks insurer decisions, calculates provider margins, issues invoices after reimbursement, and compensates recruiters from collected government money.
No single feature automatically proves fraud, yet combining no upfront cost, no payment after denial, guaranteed provider profit, reimbursement-linked invoices, billing assistance, acquisition-price questions, and commission formulas can create a concentrated collection of legal and compliance risks.
Independent review should determine whether invoices remain enforceable after denials, whether every discount is accurately disclosed, whether representatives are properly classified, whether clinical choice remains independent, and whether claims personnel can verify information without commercial pressure from vendors.
Boards and executives should also preserve contracts, spreadsheets, emails, messages, claim records, commission reports, reimbursement notices, and accounting data, because ordinary business documents can later become decisive evidence about operational control, knowledge, economic purpose, and participant intent.
Patient Care Remains the Public Interest
Skin substitutes can provide meaningful clinical benefits for properly selected chronic wounds, yet unusually lucrative reimbursement may create pressure concerning product choice, application area, treatment frequency, documentation, or patient selection when commercial returns become intertwined with clinical decisions.
The McMillan indictment focuses primarily upon alleged kickbacks, fraudulent pricing information, and reimbursement-linked payments rather than asserting that every application lacked medical value, so patients and uncharged providers should not be stigmatized through indiscriminate assumptions.
Even when a treatment offers genuine benefit, prosecutors may argue that undisclosed remuneration corrupted medical judgment or rendered the resulting claim ineligible, while the defense may contend that providers independently selected necessary products and delivered appropriate care.
The distinction matters because federal healthcare programs must protect beneficiaries and taxpayers without discouraging legitimate wound treatment, especially for patients facing diabetes, infection, circulatory impairment, immobility, severe pain, delayed healing, or possible amputation.
Corporate Reputation Moves Faster Than Litigation
An indictment can immediately dominate search results, unsettle employees, disrupt provider relationships, alarm patients, and weaken commercial confidence, even though discovery, motion practice, expert review, trial preparation, verdicts, and possible appeals may take several years.
Organizations confronting that imbalance may require disciplined crisis public-relations management that distinguishes accusations from established facts, protects confidential information, coordinates authorized statements, corrects demonstrable errors, and avoids impulsive commentary that could create further legal or reputational exposure.
Longer-term reputation-rebuilding strategies should publish accurate procedural updates, explain verified compliance reforms, preserve the presumption of innocence, and maintain consistent messaging without hiding material developments, intimidating critics, or rewriting facts established through reliable evidence.
For Protectus, McMillan, associated providers, representatives, employees, and third parties, communications must remain individualized because their legal positions differ, while careless collective statements could imply guilt, reveal protected patient information, contradict court filings, or compromise defense strategy.
What Happens Next in the McMillan Case
Pretrial proceedings may examine corporate records, electronic communications, reimbursement data, QuickBooks invoices, claim submissions, Box 19 instructions, commission reports, banking records, search procedures, expert testimony, witness credibility, and the legal boundaries governing healthcare discounts and remuneration.
Prosecutors must prove that McMillan knowingly joined the charged conspiracies and understood their unlawful purposes, while defense counsel can challenge attribution, materiality, contract interpretation, safe-harbor principles, financial tracing, provider independence, loss calculations, and the reliability of government witnesses.
If any conviction eventually occurs, sentencing would require individualized analysis of sustained counts, advisory guidelines, proven loss, role findings, criminal history, obstruction issues, accepted responsibility, victim evidence, recovered assets, and other factors considered by the presiding judge.
Until a jury returns verdicts or another lawful resolution concludes the prosecution, McMillan remains presumed innocent, Protectus remains an alleged operational vehicle rather than a proven criminal enterprise, and every disputed claim, rebate, invoice, commission, and transaction remains subject to adversarial testing.
Why Protectus LLC Matters to the Government’s Theory
The indictment’s lasting significance may depend upon whether prosecutors can prove Protectus functioned as the coordinating mechanism that transformed product distribution into a reimbursement-sharing system, connecting provider recruitment, claims assistance, payment monitoring, invoicing, representative commissions, and personal benefit.
For investigators, the Protectus records potentially provide a single documentary trail linking participants who otherwise occupied separate roles, while the defense can argue that legitimate corporate services, ordinary accounting, and lawful commercial relationships have been reorganized into an inaccurate criminal narrative.
The central question is therefore not simply whether Protectus LLC sold wound-care products, but whether McMillan allegedly used the company group to manage an intentionally concealed payment system that rewarded federally reimbursed business and misrepresented the prices providers actually paid.
